Hand transplantation is the longest established form of VCA and the first to achieve long-term functional success. It is typically indicated for patients with bilateral upper limb loss—especially at the transradial or distal level—where prosthetics offer limited function. Unilateral transplantation may be considered in select cases of dominant hand loss with severe disability. Since the first successful procedure in 1998 in Lyon, France, over 150 hand and upper limb transplants have been performed worldwide, including unilateral, bilateral, and, in rare cases, total arm transplants with brachial plexus reinnervation.

Outcomes have been especially promising in bilateral cases, with patients regaining protective sensation (pain, pressure, temperature), voluntary motor control (including power grip), and the ability to perform daily activities. Functional MRI studies show favorable cortical reintegration and restoration of sensorimotor pathways. These benefits, however, require lifelong immunosuppression and carry the risk of acute and chronic rejection.

Facial VCA represents one of the most complex and visually transformative applications of transplantation surgery. Indications include severe facial disfigurement from trauma, burns, cancer, or congenital deformities, where conventional reconstruction fails to restore key functions such as speech, breathing, mastication, and emotional expression. ^,

Since the first partial face transplant in 2005 in France, over 50 face transplants have been performed worldwide, involving various components, including the scalp, ears, nose, lips, eyelids, and underlying skeletal structures. ^, Functional outcomes have been remarkable. Patients often recover facial sensation within several months and gradually regain voluntary motor control, including the ability to blink, smile, or chew. In some cases, olfactory and gustatory functions have returned. Psychosocial integration is equally important: face transplantation has enabled many recipients to re-enter society, resume employment, and experience significant improvements in self-esteem and mental health.

Despite these successes, challenges remain. Acute rejection episodes are common, and chronic rejection remains a significant concern and can lead to loss of graft function or even graft loss. The management of chronic rejection is still evolving, and long-term outcomes are not yet fully understood.

Uterus transplantation , developed to treat absolute uterine factor infertility, has resulted in over 45 live births worldwide. As a non-vital, temporary graft, the uterus is typically removed after one or two pregnancies to mitigate long-term immunosuppression risks. This procedure has expanded reproductive surgery, offering a direct treatment for a previously untreatable condition, though it raises ethical concerns regarding donor and recipient risks.

Penile transplantation , indicated for traumatic or oncologic loss, has shown restored urinary and sexual function—including erections and ejaculation—in a few successful cases in South Africa, the United States, and China. Its psychosocial impact is especially significant for young trauma survivors. ^,

Laryngeal transplantation , though exceedingly rare, can restore phonation and airway protection. Fewer than 5 cases have been reported, all requiring precise nerve coaptation and tailored immunosuppression due to high immunogenicity.

Abdominal wall transplantation has addressed complex abdominal defects in intestinal and multivisceral transplant patients. It facilitates abdominal closure, restores structural integrity, and serves as a sentinel marker for rejection, aiding visceral graft monitoring.

Lower extremity transplantation has been performed in fewer than 10 cases worldwide. The first successful case showed good 6 year functional outcomes. Its rarity is due to advanced prosthetics that provide excellent functional outcomes and the high risks of immunosuppression, rejection, and complex perioperative care. Nevertheless, it remains an option in select cases, as it offers biological restoration of sensory and motor function.

The development of VCA has been largely driven by the needs of military personnel and civilian trauma survivors. Following the Iraq and Afghanistan conflicts, many young veterans returned with severe blast injuries—especially bilateral upper limb and facial defects—poorly addressed by conventional reconstruction. Institutions such as the U.S. Department of Defense have heavily invested in VCA research and infrastructure, advancing surgical techniques, immunosuppression, and rehabilitation.

The current standard for rehabilitation has long been the prosthetic limb, ranging from basic cosmetic prostheses to advanced myoelectric hands. They offer immediate function without the need for immunosuppression but are limited by poor sensory feedback, restricted fine motor control, and the cognitive burden of visually guided use. These drawbacks often impede full restoration of normalcy and self-esteem.

In contrast, hand transplantation allows near-anatomic restoration, with many patients regaining protective and tactile sensation as well as proprioception—critical for fine motor tasks. ^, Esthetic outcomes are typically superior, especially when donor–recipient skin tone and hair are matched. Functional recovery progresses over time, with patients often able to perform tasks like buttoning a shirt or using utensils within 1 to 2 years. ^,, Transplant recipients report higher satisfaction and improved self-esteem compared to prosthetic users, despite the need for lifelong immunosuppression. However, this benefit is not universal; some recipients have required graft removal due to rejection or functional stagnation, while others have voluntarily reverted to prosthetics due to complications or disappointment. Nonetheless, not all cases succeed; some require graft removal or a return to prosthetics due to complications. Although hand transplantation incurs higher initial costs due to operative and immunologic demands, long-term expenses may converge with prosthetic care, which includes maintenance and replacement. However, insurance coverage for transplantation remains inconsistent.

Facial disfigurement following trauma, burns, or cancer surgery has devastating functional, social, and psychological consequences. Traditional reconstruction, such as local or free tissue transfer, restores coverage and partial form but often fails to replicate complex facial contours and expressive movement. External prostheses can conceal defects but function largely as static masks.

Facial VCA offers anatomically faithful and dynamic reconstruction using composite grafts of skin, fat, muscle, cartilage, bone, and nerves. This allows restoration of facial symmetry, expression, oral competence, and nasal airflow. Many recipients regain the ability to smile, speak intelligibly, and eat normally. Psychologically, facial VCA can be transformative, restoring a sense of identity and social reintegration. ^,, However, patients may struggle with adopting donor features, underscoring the need for robust psychological support. Facial VCA poses substantial challenges, including difficulty obtaining donor consent, high rates of acute rejection (>85% in the first year), chronic rejection risk (eg, vasculopathy, graft loss), and frequent opportunistic infections. ^,, The need for lifelong immunosuppression comes with long-term risk, including renal toxicity, often due to the nephrotoxic effects of calcineurin inhibitors like tacrolimus, and malignancy, particularly skin cancers and lymphoproliferative disorders. ^,

Facial transplantation is costly—ranging from $250,000 to $1.5 million—but long-term costs may align with traditional reconstruction, which often involves multiple complex procedures. In carefully selected patients with no viable alternatives, VCA may offer the only path to meaningful recovery. Though limited in sample size, comparative studies consistently show superior quality-of-life outcomes in facial VCA recipients compared to those with masks or flaps. ^,

Complex abdominal wall defects, especially in the presence of enterocutaneous fistulas, contamination, or significant loss of domain, are difficult to manage. Traditional methods include synthetic mesh, bioprosthetics, component separation, and autologous flaps. While often effective, these approaches may be inadequate for full-thickness defects or highly contaminated fields.

Abdominal wall VCA offers a one-step reconstruction using dynamic musculature, vascularized fascia, and full-thickness skin, with potential for reinnervation and functional restoration. It is primarily performed in conjunction with multivisceral or intestinal transplantation, where other options are unfeasible. Reported benefits include improved abdominal tone, prevention of hernia recurrence, and esthetic symmetry, especially in patients with failed prior reconstructions. However, as with other forms of VCA, risks include surgical complexity, immunosuppression-related complications, and rejection. Patient selection must be carefully considered, particularly in those with comorbidities or transplant history.

Assessing VCA outcomes is challenging due to small, diverse patient cohorts. Still, early data indicate superior results in fine motor control (hand), expressive function (face), and structural support (abdominal wall) compared to traditional reconstruction. ^,

Though VCA entails high initial costs and lifelong immunosuppression, it may lower long-term expenses by reducing the need for revisions, prosthetics, and psychosocial interventions. QALY analyses suggest the functional and psychological gains can justify the investment for select patients. ^,,

The choice between VCA and conventional options should be individualized, balancing function, risks, psychosocial needs, and resources. Rather than replacing standard methods, VCA may serve as a valuable adjunct for the most complex cases. Table 1 summarizes the current VCA types and associated outcomes.

One of the most pressing concerns in VCA is the requirement for lifelong immunosuppression to prevent graft rejection. Unlike solid organ transplants, which replace life-sustaining organs like the heart, liver, or kidney, VCA aims to enhance quality of life rather than extend it. This distinction presents an ethical dilemma: Is it justifiable to expose patients to the substantial risks of chronic immunosuppression for a non-life-saving procedure?

Immunosuppressive drugs carry numerous adverse effects, including opportunistic infections, nephrotoxicity, diabetes, hypertension, and increased malignancy risk. Thus, balancing quality-of-life improvement with the burden of lifelong therapy is central to patient selection and informed consent. Despite strict adherence to immunosuppression, patients remain at risk for both acute and chronic rejection. Managing rejection in VCA is challenging, with rates and presentations varying by transplant type. Acute rejection affects over 85% of hand and face transplant recipients in the first year, typically presenting with erythema, edema, or mucosal changes detectable by visual inspection. ^, Histologic features of face transplant rejection include interface dermatitis with keratinocyte apoptosis, subcutaneous vessel wall hyalinization, endothelial degeneration, lymphocytic vasculitis, and dermal sclerosis, with chronic rejection often showing obliterative endarteritis-like changes and pan-fibrosis indicative of graft vasculopathy. While often reversible with steroids or topical agents, recurrent episodes may predispose to chronic rejection. ^, Abdominal wall transplants show lower reported rejection rates, though data remain limited. In uterus transplantation, acute rejection episodes are less well documented but likely follow similar pathways.

Chronic rejection in VCA remains poorly defined. Its incidence is unknown, and timing likely varies. In face transplants, chronic rejection—marked by graft fibrosis and functional decline—may result from repeated acute episodes or graft vasculopathy, observed in cases of terminal graft failure. ^,, Similar to solid organ transplants, VCA chronic rejection often involves transplant vasculopathy, characterized by intimal proliferation, immune cell infiltration, and cytokine-mediated inflammation leading to intimal thickening and eventual vessel occlusion. All VCA types face the added complexity of multi-tissue immunogenicity, where skin and mucosal components (particularly in face/uterus transplants) drive stronger immune responses compared to deeper tissues. Although skin is traditionally considered the most immunogenic component of skin-containing VCAs, emerging evidence suggests that mucosa may be more sensitive to allograft rejection in facial VCAs.

Lastly, the need for lifelong high-dose immunosuppression introduces risks of infections, metabolic complications, and viral reactivations (eg, cytomegalovirus, Epstein-Barr virus), as well as malignancies, which may further exacerbate rejection risks.

To balance graft preservation with reduced immunosuppression risks, various strategies have been explored. Induction regimens typically combine anti-thymocyte globulin, tacrolimus, mycophenolate mofetil (MMF), and corticosteroids, with some also including anti-lymphocyte serum to enhance lymphocyte depletion and graft tolerance. The standard maintenance regimen in most centers involves triple therapy: tacrolimus (a calcineurin inhibitor), MMF (an antiproliferative), and corticosteroids, effectively reducing early rejection and preserving long-term graft viability, albeit with cumulative toxicity.

To address this, tapering strategies are used postoperatively in select patients. Steroid reduction or discontinuation is prioritized due to long-term metabolic side effects. VCA recipients have been successfully weaned off maintenance steroids after a median of 2 months, maintaining graft function with dual therapy (tacrolimus and MMF/mycophenolic acid). This reduces toxicity while preserving efficacy, though tapering must be cautiously balanced against risks of subclinical or late rejection, requiring close biopsy and immune monitoring.

Innovative protocols aim to induce tolerance and eliminate lifelong immunosuppression. Mixed chimerism—via donor bone marrow infusion, non-myeloablative conditioning, and costimulatory blockade—has shown promise in preclinical models, enabling long-term tolerance without chronic immunosuppression. Regulatory T-cell therapies have also shown benefits in experimental VCA models. However, these approaches remain experimental, with inconsistent results in VCA and other transplant types. Myeloablative conditioning and precise timing of bone marrow transplantation pose logistical hurdles, such as the need for total body irradiation. Despite these challenges, ongoing trials and preclinical studies continue refining these methods, offering a potential path to safer, more sustainable transplantation.